BACKGROUND: To understand whether the association between Epstein-Barr Virus (EBV) and gastric cancer (GC) has any role in loss of surface expression of human lymphocyte antigen (HLA) class I, the authors analyzed locus-specific transcriptional expression of HLA-A, HLA-B, HLA-C, and HLA-E along with other HLA-associated molecules (beta2-microglobulin [beta2M], cellular latent membrane protein [LMP], and transporter associated with antigen presentation [TAP]) in EBV-associated, primary GC (EBVaGC) and EBV-negative GC (EBVnGC) tissues. METHODS: Approximately 20 EBVaGC tissues and 40 EBVnGC tissues and their corresponding normal tissues were used in the study. The presence of EBV in GC was established by EBV-encoded small RNA in situ hybridization analysis and BamHI W polymerase chain reaction (PCR) analysis. Transcriptional expression of viral LMP2A and several HLA class I genes were analyzed by reverse transcriptase (RT)-PCR. Surface expression levels of HLA class I proteins in cancer samples along with their normal counterparts also were quantified by flow cytometry. RESULTS: The RT-PCR data suggested selective down-regulation of the HLA-A/HLA-B locus along with over-expression of HLA-E transcripts in EBVaGC (P < .05). This was confirmed further by the flow-cytometric studies using antibodies to HLA-ABC and HLA-E. Among the accessory molecules, LMP7 transcript was down-regulated in a number of EBVaGC tissues compared with EBVnGC. CONCLUSIONS: The current results suggested that the establishment of EBV latent infection in gastric tissues allows malignant cells to avoid the immune surveillance of both cytotoxic T-lymphocytes and natural killer cells by regulating the differential expression of HLA class I molecules. 2006 American Cancer Society
BACKGROUND: To understand whether the association between Epstein-Barr Virus (EBV) and gastric cancer (GC) has any role in loss of surface expression of human lymphocyte antigen (HLA) class I, the authors analyzed locus-specific transcriptional expression of HLA-A, HLA-B, HLA-C, and HLA-E along with other HLA-associated molecules (beta2-microglobulin [beta2M], cellular latent membrane protein [LMP], and transporter associated with antigen presentation [TAP]) in EBV-associated, primary GC (EBVaGC) and EBV-negative GC (EBVnGC) tissues. METHODS: Approximately 20 EBVaGC tissues and 40 EBVnGC tissues and their corresponding normal tissues were used in the study. The presence of EBV in GC was established by EBV-encoded small RNA in situ hybridization analysis and BamHI W polymerase chain reaction (PCR) analysis. Transcriptional expression of viral LMP2A and several HLA class I genes were analyzed by reverse transcriptase (RT)-PCR. Surface expression levels of HLA class I proteins in cancer samples along with their normal counterparts also were quantified by flow cytometry. RESULTS: The RT-PCR data suggested selective down-regulation of the HLA-A/HLA-B locus along with over-expression of HLA-E transcripts in EBVaGC (P < .05). This was confirmed further by the flow-cytometric studies using antibodies to HLA-ABC and HLA-E. Among the accessory molecules, LMP7 transcript was down-regulated in a number of EBVaGC tissues compared with EBVnGC. CONCLUSIONS: The current results suggested that the establishment of EBV latent infection in gastric tissues allows malignant cells to avoid the immune surveillance of both cytotoxic T-lymphocytes and natural killer cells by regulating the differential expression of HLA class I molecules. 2006 American Cancer Society
Authors: Marloes Gooden; Margit Lampen; Ekaterina S Jordanova; Ninke Leffers; J Baptist Trimbos; Sjoerd H van der Burg; Hans Nijman; Thorbald van Hall Journal: Proc Natl Acad Sci U S A Date: 2011-06-13 Impact factor: 11.205
Authors: Mark J Cameron; Longsi Ran; Luoling Xu; Ali Danesh; Jesus F Bermejo-Martin; Cheryl M Cameron; Matthew P Muller; Wayne L Gold; Susan E Richardson; Susan M Poutanen; Barbara M Willey; Mark E DeVries; Yuan Fang; Charit Seneviratne; Steven E Bosinger; Desmond Persad; Peter Wilkinson; Larry D Greller; Roland Somogyi; Atul Humar; Shaf Keshavjee; Marie Louie; Mark B Loeb; James Brunton; Allison J McGeer; David J Kelvin Journal: J Virol Date: 2007-05-30 Impact factor: 5.103
Authors: Chenhe Su; Fang Lu; Samantha S Soldan; R Jason Lamontagne; Hsin-Yao Tang; Giorgia Napoletani; Paul J Farrell; Italo Tempera; Andrew V Kossenkov; Paul M Lieberman Journal: PLoS Pathog Date: 2021-08-05 Impact factor: 7.464
Authors: Mepur H Ravindranath; Fatiha El Hilali; Carly J Amato-Menker; Hajar El Hilali; Senthamil R Selvan; Edward J Filippone Journal: Antibodies (Basel) Date: 2022-09-08
Authors: Bert A 't Hart; S Anwar Jagessar; Krista Haanstra; Ernst Verschoor; Jon D Laman; Yolanda S Kap Journal: Front Immunol Date: 2013-06-13 Impact factor: 7.561